

ASX Release**Oventus enters into first agreements with American sleep medicine groups to deliver the O₂Vent® Sleep Treatment Platform to patients under the 'lab in lab' model****Key points:**

- **Oventus signs first material agreements with sleep medicine groups in the United States for its O₂Vent® Sleep Treatment Platform which treats obstructive sleep apnoea (OSA)**
- **The exclusive agreements to supply dental sleep medicine solutions are with 8 sleep facilities in Texas, Arizona and New Mexico**
- **Contracts further validate demand for Oventus sleep treatment platform and 'lab in lab' delivery model**
- **Oventus expects to secure further agreements across North America over the next 12-24 months**
- **Negotiations ongoing with multiple groups across Canada, the US and Australia with a view to significant scaling through the end of calendar 2019 and 2020**

Brisbane, Australia 15 July 2019: Oventus Medical Ltd or the Company (ASX: OVN) is pleased to announce it has signed its first material contract with an American sleep medicine group which will adopt the Company's O₂Vent® treatment platform for the treatment of obstructive sleep apnoea (OSA) across 8 clinical treatment sites.

The agreement identifies Oventus as the primary supplier for oral appliances for the treatment of OSA. The agreement reaches across three states: Texas, Arizona and New Mexico where minimum monthly quota of 20 O₂Vent® devices will be delivered to patients, per site. Due to large volumes of patients, device orders are expected to exceed these quotas once fully operational. The agreement will be officially launched as soon as the O₂Vent® Optima oral device has received regulatory clearance from the US FDA.

CEO of Oventus, Dr Chris Hart commented, "This is an important agreement as it is the first we've announced in the US which will use our 'lab in lab' business model and one that we have signed in anticipation of FDA clearance of the company's flagship device the O₂Vent® Optima. It further validates the growing interest in our sleep apnoea treatment platform and the business model which benefits both patients and treatment providers.

This US agreement follows our announcement last month that the first 7 sites had signed up in Canada under the same model, also committed to selling minimum quantities of our O₂Vent® Optima devices. There are a number of additional contracts being negotiated in Canada where both O₂Vent® Optima and Oventus' unique oral PEEP valve, ExVent™ are both cleared for sale. We are working through the set-up process for the first 7 sites in Canada now and are hopeful that FDA approval for the O₂Vent® Optima will occur shortly so that we can enable these US agreements soon after completing our initial Canadian deployments."

In the meantime, a significant further pipeline of potential agreements exists with multiple groups across Canada, the US and Australia. The pipeline is being driven by growing awareness from clinicians that the O₂Vent® technology can deliver outcomes comparable to the standard of care – continuous positive airway pressure technology (CPAP) – for the majority of patients in a non-invasive manner. The ‘lab in lab’ model, which delivers fast outcomes for patients within a framework that is commercially attractive for sleep labs has also been a key driver.

Further agreements of this kind are expected to be secured and announced across these key markets over the next 12-24 months.

—ENDS—

For further information, please visit our website at www.o2vent.com or contact the individuals outlined below.

Dr Chris Hart, Managing Director and CEO: M: +61 409 647 496

Jane Lowe, IR Department: M: +61 411 117 774 or jane.lowe@irdepartment.com.au

About Oventus – see more at www.o2vent.com

Oventus is a Brisbane based medical device company that is commercialising a unique treatment platform for sleep apnoea and snoring. The Company has a collaborative Sleep Physician/ Dental strategy that streamlines patients’ access to treatment. The Oventus lab model incorporates digital technology via intra oral scanning to achieve operational efficiencies, accuracy and ultimately patient outcomes.

Unlike other oral appliances or CPAP interfaces, Oventus O₂Vent® devices manage the entire upper airway via a unique and patented built-in airway. O₂Vent® devices allow for airflow to the back of the mouth while maintaining an oral seal and stable jaw position, bypassing multiple obstructions from the nose, soft palate and tongue. The devices reduce airway collapsibility and manage mouth breathing while keeping the airway stable.

O₂Vent® devices are particularly designed for the many people that have nasal obstruction. They allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.

The ExVent™ is a valve accessory that fits into the open airway of the O₂Vent® Optima device, to augment traditional oral appliance therapy by stabilising the airway. The ExVent™ valve contains air vents that open fully on inhalation for unobstructed airflow. The valve closes on exhalation, directing the air through the vents, creating the mild resistance or airway support required to keep the airway stable (known as PEEP, positive end expiratory pressure).

According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea.¹

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnoea, however many patients have difficulty tolerating CPAP². Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnoea treatment³. The O₂Vent® Optima and ExVent™ provide a discreet and comfortable alternative to CPAP for the treatment of OSA.

¹ Deloitte Access Economics. Reawakening Australia: the economic cost of sleep disorders in Australia, 2010. Canberra, Australia.

² Beecroft, et al. Oral continuous positive airway pressure for sleep apnea; effectiveness, patient preference, and adherence. Chest 124:2200–2208, 2003

³ Sutherland et al. Oral appliance treatment for obstructive sleep apnea: An updated Journal of Clinical Sleep Medicine. February 2014.